Roctavian, like many other gene therapies and oncology produ…
Roctavian, like many other gene therapies and oncology products, received market authorization from the FDA based primarily on single-arm trial data. In your view, what is the main problem with relying on single-arm trial data to assess the efficacy of a new treatment? To assess the comparative effectiveness of a new drug when only single-arm trial data is available, a common approach is to combine the single-arm trial data with a so-called external/historical control group. Describe why adding data from an external and/or historical control group may be relevant and what are the advantages and disadvantages with this approach? Your response should be 250 to 500 words (½ to 1 page).
Read DetailsAn 18-year-old woman in whom a sexually transmitted disease…
An 18-year-old woman in whom a sexually transmitted disease (STD) was recently diagnosed asks the nurse practitioner not to tell her mother that she has an STD. Her mother asks what is causing her daughter’s vaginal discharge. Which of the following actions should the nurse practitioner take?
Read DetailsA client reports that they doubt they will ever develop lung…
A client reports that they doubt they will ever develop lung cancer, as their parents made the same lifestyle choices and were never diagnosed with lung issues. This is an example of which construct of the health belief model?
Read Details